Patronus Biotech secures regulatory approval for malaria vaccine trials in Australia
Patronus Biotech has received ethical clearance to commence phase 1 human trials for three multi-stage malaria vaccine candidates in Australia.
The Human Research Ethics Committee at Bellberry Limited has granted approval for Patronus Biotech to conduct a phase 1 clinical trial. The study focuses on evaluating the safety and tolerability of three multi-stage vaccine candidates designed to combat malaria.
Malaria remains a major global public health concern, with current vaccine development focused on multi-stage protection to prevent infection and disease transmission. The study in Australia marks the transition of these candidates from laboratory settings into controlled human testing environments.
This trial represents a milestone for Patronus Biotech as it seeks to gather primary data on human immune responses. The outcomes of this initial phase will be instrumental in determining the viability of the candidates for future large-scale clinical trials.